Intractable disease therapeutic supplements KIDNIOME (right) and PETMUNIOME launched by Anybiome Inc. / Photo=Anybiome
Therapeutic supplements for intractable animal diseases have been developed by current professors at Seoul National University College of Veterinary Medicine, including the nation's leading authority on intractable animal diseases. Since the launch announcement, inquiries have been pouring in from pet enthusiast communities, according to Anybiome Inc. on the 23rd.
Anybiome Inc. (CEO Jang Woon-sang), a bio startup founded by four professors from Seoul National University College of Veterinary Medicine, officially launched two health functional therapeutic supplements last week: 'PETMUNIOME' and 'KIDNIOME,' solutions designed to help manage intractable diseases in companion animals.
Recently, as the average lifespan of companion animals has increased and a social atmosphere of considering them as family members has become established, the demand for chronic disease treatment has surged. However, with limited diagnostic, pharmaceutical, and surgical options available for companion animals, the probability of achieving good prognosis in intractable diseases—which are difficult even for humans—falls short of expectations.
The reality is that pet owners, desperate for any help, are searching everywhere for health functional therapeutic supplements that can aid recovery alongside treatments available from existing medical institutions.
According to the company, these two supplements are 'Multi-Mechanism Therapeutic Supplement Solutions' that can simultaneously care for the three key axes of 'kidney-immunity-gut,' which are essential for managing intractable diseases in companion animals. Prior to launch, pilot clinical trials were conducted, and unusually for pilot clinical trials, the results were published in two academic journals, attracting international attention.
In the case of 'KIDNIOME,' pilot clinical trials conducted at Seoul National University College of Veterinary Medicine on cats with end-stage renal failure showed that ammonia, a major cause of renal failure, improved by up to 46.3%, and creatinine levels improved by 27.6%, according to Anybiome Inc. Renal failure, which is known to occur in more than 30% of cats over 10 years old, is also the disease that cat owners are most wary of.
The company published these research results in the international veterinary journal 'Veterinary Integrative Sciences' for academic verification. The company plans to continue rigorous clinical trials meeting therapeutic drug standards, as their ultimate goal is approval as a therapeutic drug.
'PETMUNIOME,' launched alongside KIDNIOME, was developed for improving immunity in companion animals and is a complex formulation composed of probiotics with Dendropanax morbiferus (golden-leaf tree) as the main ingredient.
'PETMUNIOME' also achieved results in pilot clinical trials conducted at Seoul National University College of Veterinary Medicine on dogs with terminal cancer, showing a 48.2% improvement in lymphocytes, a major cancer indicator, and a 21.3% improvement in inflammation markers. These research results were published in the 'J APPL BIOL CHEM' journal.
International veterinary journal 'Veterinary Integrative Sciences' (top), 'J APPL BIOL CHEM' (bottom) / Photo=Anybiome
Dendropanax morbiferus, the main ingredient of 'PETMUNIOME,' is a plant native to the southern regions of South Korea and has been called the 'Emperor's Tree' since ancient times. As research results on its effectiveness in treating neurological conditions have been published in domestic and international papers, there has been active movement not only in animal treatment but also in new drug development for intractable neurological diseases such as post-herpetic neuralgia.
Anybiome stated that clinical trials are not a prerequisite for launching health functional therapeutic supplements, and in fact, not many companies in the animal health supplement market conduct clinical trials. However, since the goal of both products is approval as official therapeutic drugs, they will continue to conduct additional clinical trials.
From top left clockwise – Professor Won-seok Oh, Professor Min-su Kim, Professor Sung-bum Cho, Professor Seung-jun Baek / Photo=Anybiome
Professor Won-seok Oh of Seoul National University College of Veterinary Medicine, a founding member of Anybiome, is known as Korea's top expert in treating chronic intractable diseases in animals. Joining Professor Oh are Professor Min-su Kim, Professor Sung-bum Cho, and Professor Seung-jun Baek from Seoul National University College of Veterinary Medicine.
Both products are currently available for purchase on Anybiome's official online store.
Intractable diseases in companion animals refer to chronic and complex conditions that are difficult to cure with conventional treatments, such as cancer, renal failure, heart disease, arthritis, and corneal ulcers.
Source: Segye Biz & Sports World
Intractable disease therapeutic supplements KIDNIOME (right) and PETMUNIOME launched by Anybiome Inc. / Photo=AnybiomeTherapeutic supplements for intractable animal diseases have been developed by current professors at Seoul National University College of Veterinary Medicine, including the nation's leading authority on intractable animal diseases. Since the launch announcement, inquiries have been pouring in from pet enthusiast communities, according to Anybiome Inc. on the 23rd.
Anybiome Inc. (CEO Jang Woon-sang), a bio startup founded by four professors from Seoul National University College of Veterinary Medicine, officially launched two health functional therapeutic supplements last week: 'PETMUNIOME' and 'KIDNIOME,' solutions designed to help manage intractable diseases in companion animals.
Recently, as the average lifespan of companion animals has increased and a social atmosphere of considering them as family members has become established, the demand for chronic disease treatment has surged. However, with limited diagnostic, pharmaceutical, and surgical options available for companion animals, the probability of achieving good prognosis in intractable diseases—which are difficult even for humans—falls short of expectations.
The reality is that pet owners, desperate for any help, are searching everywhere for health functional therapeutic supplements that can aid recovery alongside treatments available from existing medical institutions.
According to the company, these two supplements are 'Multi-Mechanism Therapeutic Supplement Solutions' that can simultaneously care for the three key axes of 'kidney-immunity-gut,' which are essential for managing intractable diseases in companion animals. Prior to launch, pilot clinical trials were conducted, and unusually for pilot clinical trials, the results were published in two academic journals, attracting international attention.
In the case of 'KIDNIOME,' pilot clinical trials conducted at Seoul National University College of Veterinary Medicine on cats with end-stage renal failure showed that ammonia, a major cause of renal failure, improved by up to 46.3%, and creatinine levels improved by 27.6%, according to Anybiome Inc. Renal failure, which is known to occur in more than 30% of cats over 10 years old, is also the disease that cat owners are most wary of.
The company published these research results in the international veterinary journal 'Veterinary Integrative Sciences' for academic verification. The company plans to continue rigorous clinical trials meeting therapeutic drug standards, as their ultimate goal is approval as a therapeutic drug.
'PETMUNIOME,' launched alongside KIDNIOME, was developed for improving immunity in companion animals and is a complex formulation composed of probiotics with Dendropanax morbiferus (golden-leaf tree) as the main ingredient.
'PETMUNIOME' also achieved results in pilot clinical trials conducted at Seoul National University College of Veterinary Medicine on dogs with terminal cancer, showing a 48.2% improvement in lymphocytes, a major cancer indicator, and a 21.3% improvement in inflammation markers. These research results were published in the 'J APPL BIOL CHEM' journal.
International veterinary journal 'Veterinary Integrative Sciences' (top), 'J APPL BIOL CHEM' (bottom) / Photo=AnybiomeDendropanax morbiferus, the main ingredient of 'PETMUNIOME,' is a plant native to the southern regions of South Korea and has been called the 'Emperor's Tree' since ancient times. As research results on its effectiveness in treating neurological conditions have been published in domestic and international papers, there has been active movement not only in animal treatment but also in new drug development for intractable neurological diseases such as post-herpetic neuralgia.
Anybiome stated that clinical trials are not a prerequisite for launching health functional therapeutic supplements, and in fact, not many companies in the animal health supplement market conduct clinical trials. However, since the goal of both products is approval as official therapeutic drugs, they will continue to conduct additional clinical trials.
From top left clockwise – Professor Won-seok Oh, Professor Min-su Kim, Professor Sung-bum Cho, Professor Seung-jun Baek / Photo=AnybiomeProfessor Won-seok Oh of Seoul National University College of Veterinary Medicine, a founding member of Anybiome, is known as Korea's top expert in treating chronic intractable diseases in animals. Joining Professor Oh are Professor Min-su Kim, Professor Sung-bum Cho, and Professor Seung-jun Baek from Seoul National University College of Veterinary Medicine.
Both products are currently available for purchase on Anybiome's official online store.
Intractable diseases in companion animals refer to chronic and complex conditions that are difficult to cure with conventional treatments, such as cancer, renal failure, heart disease, arthritis, and corneal ulcers.
Source: Segye Biz & Sports World